Skip to main content

Vantage Drilling International Ltd. – Announcement of Contract Termination

Dubai, Oct. 19, 2025 (GLOBE NEWSWIRE) — Vantage Drilling International Ltd. (the “Company”) announces the immediate termination of the contract for the Platinum Explorer for its approximately 260-day campaign. The termination is due to changes in economic sanctions applicable to the campaign, rendering the contract execution unlawful and therefore subject to termination. This information has been submitted pursuant to Section 5-12 of the Norwegian Securities Trading Act and MAR Article 17. The information was submitted for publication at 2025-10-19 at 7:30 CEST. About the Company Vantage Drilling International Ltd., a Bermuda exempted company, is an offshore drilling contractor. Vantage Drilling’s primary business is to contract drilling units, related equipment and work crews primarily on a dayrate basis to drill oil and...

Continue reading

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)1Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings2,3The safety profile and tolerability of Pluvicto in this third positive Phase III study were consistent with its established profile in PSMAfore and VISION trials1,4,5Novartis plans to submit to regulatory authorities by end of year; potential approval would double the number of patients eligible for Pluvicto and further establish its efficacy in metastatic prostate cancer settingsBasel, October 19, 2025 – Novartis...

Continue reading

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m² LONDON and PHILADELPHIA, Oct. 19, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, today announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000) to be presented at the 2025 European Society of Medical Oncology Annual...

Continue reading

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P). The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of response of 11.9 months (3.9, not reached). The safety profile was favorable with generally transient grade 1 and 2 treatment related adverse events. Acral melanoma is a rare and aggressive type of cutaneous...

Continue reading

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025. RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate...

Continue reading

Sify Technologies to announce Financial Results for Second Quarter FY 2025-26 on Saturday, October 25, 2025

CHENNAI, India, Oct. 18, 2025 (GLOBE NEWSWIRE) — Sify Technologies Limited (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the second quarter ended September 30, 2025 on Saturday, October 25, 2025 before the market opens.  The following Monday, October 27, 2025, Sify will host a conference call at 8:30 AM ET with Mr. Raju Vegesna, Chairman of the Board and Mr. M P Vijay Kumar, Executive Director & Group CFO. Interested parties may participate by dialling +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International), which will also be simultaneously broadcast live over the Internet at www.sifytechnologies.com/investors...

Continue reading

Nasdaq Halts Etoiles Capital Group Co., Ltd.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Etoiles Capital Group Co., Ltd. (Nasdaq: EFTY) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in EFTY from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $15.02.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104163.pdf. Trading will remain halted until Etoiles Capital Group Co., Ltd. has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM...

Continue reading

Nasdaq Halts Platinum Analytics Cayman Limited

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Platinum Analytics Cayman Limited (Nasdaq: PLTS) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PLTS from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $17.50.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104164.pdf. Trading will remain halted until Platinum Analytics Cayman Limited has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM...

Continue reading

Nasdaq Halts Pitanium Limited

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Pitanium Limited (Nasdaq: PTNM) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PTNM from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $10.39.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104165.pdf. Trading will remain halted until Pitanium Limited has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site. For...

Continue reading

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma (“RCC”). Using patient-derived organoids (“PDOs”) from ten patients with RCC and autologous tumor-infiltrating lymphocytes (“TILs”), co-culture experiments reveal that NUC-7738 enhances the effectiveness of PD-1 inhibitors, resulting in increased tumor cell killing. This combinatorial approach may offer a new option for cancers that no longer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.